Download Free Brand Plan Rx Book in PDF and EPUB Free Download. You can read online Brand Plan Rx and write the review.

Healthcare and pharmaceutical marketing executives, professor Markus Saba and marketer Hilary Gentile, provide a step-by-step formula to uncover the unique needs that drive brand choice in the health and wellness industry.
How can I build my brand when it is just another me-too? is the quintessential question asked by pharma and healthcare marketers operating in the branded generic markets. In highly saturated markets with hundreds of similar brands, establishing a competitive edge and building a strong brand is often a challenging task. The Perfect Pill propagates a robust 10-step healthcare brand-building model that helps you create much-needed differentiation and a unique value proposition for patients and physicians. The steps suggested in the book help establish an ultimate win-win situation for patients, physicians, and sales and marketing professionals. A must-read for pharmaceutical, medical device, diagnostic, over-the-counter, surgical, hospital, nutrition, and wellness brand marketers.
Written by John Lidstone and Janice MacLennan, the second edition of Marketing Planning for the Pharmaceutical Industry became accepted as the bible for the industry. In this new companion book Janice MacLennan picks up two of the themes touched on in Marketing Planning - market segmentation and branding, and the inter-relationship between these two - and with this book makes them key topics for discussion. Brand Planning for the Pharmaceutical Industry begins by exploring what branding is and why it is of importance, particularly to the pharmaceutical sector. The book then goes on to show how branding can be integrated into the early stages of the commercialization process for new products, both in theory and in the 'real' world. The book provides a step-by-step guide to brand planning, using market segmentation as the starting point. The book is split into two parts, the first dealing comprehensively with brand planning for products yet to get to the market, with the second part applying the same process to products that are already on the market. Both parts are extremely pragmatic, full of pertinent examples and insights from the pharmaceutical industry, and are directly applicable to your own brand planning. Brand Planning for the Pharmaceutical Industry concludes by confronting the problems that organizations are likely to have in actually making brand planning an integral part of their work and presents strategies for dealing with them.
The pharma and medtech sectors are evolving rapidly, driven by science, technology, economics, politics and globalization. In the new industry landscape, creating strong brand strategies is ever more difficult and ever more vital. Brand Therapy gives pharma and medtech brand teams the tools to understand their market, create strong strategies and translate them into actionable plans. Written in 16 short, easy chapters, it is essential reading for anyone who works in or with brand teams in the life sciences industry.
Donovan Boyd, "The Marketing Coach," is a passionate, hardworking, attentive business man, and the CEO of The Boyd Group, LLC. Not only does Donovan hold a bachelor's degree in Business Administration with a concentration in Marketing from Fordham University, and an MBA from South University, his professional background consist of 10 years of marketing and brand management experience in education, music, entertainment, and private consulting. Prior to starting The Boyd Group, Donovan served as an intern in the urban marketing department for Atlantic Records and served as a volunteer coordinator for Russell Simmons' Hip Hop Summit Action Network. He spent 2 years as a Marketing Director for a local charter school in Cleveland, OH while maintaining an artist management and promotional company for 4 years. Since then, he created the credible business coaching firm called, The Boyd Group, LLC, with the mission to help businesses & individuals unlock their brand potential through innovative strategies that create brand value & aid customer loyalty. Donovan's passion is to travel the country and educate people on the growth opportunities within their business. His latest book, The Brand Playbook, is the precise tool needed for new and future entrepreneurs. Through Donovan's varied background, he has set the perfect foundation for effective branding and marketing as "The Marketing Coach."
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Millions of Americans are taking prescription drugs made in China and don't know it-- and pharmaceutical companies are not eager to tell them. This probing book examines the implications for the quality and availability of vital medicines for consumers. Several decades ago, penicillin, vitamin C, and many other prescription and over-the-counter products were manufactured in the United States. But with the rise of globalization, antibiotics, antidepressants, birth control pills, blood pressure medicines, cancer drugs, among many others are made in China and sold in the United States. China's biggest impact on the US drug supply is making essential ingredients for thousands of medicines found in American homes and used in hospital intensive care units and operating rooms. The authors convincingly argue that there are at least two major problems with this scenario. First, it is inherently risky for the United States to become dependent on any one country as a source for vital medicines, especially given the uncertainties of geopolitics. For example, if an altercation in the South China Sea causes military personnel to be wounded, doctors may rely upon medicines with essential ingredients made by the adversary. Second, lapses in safety standards and quality control in Chinese manufacturing are a risk. Citing the concerns of FDA officials and insiders within the pharmaceutical industry, the authors document incidents of illness and death caused by contaminated medications that prompted reform. This is a disturbing, well-researched book and a wake-up call for improving the current system of drug supply and manufacturing.
A NEW YORK TIMES BESTSELLER * New York Times Notable Book * Best Book of the Year: New York Public Library, Kirkus Reviews, Science Friday With a new postscript by the author From an award-winning journalist, an explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers on a global scale—The Jungle for pharmaceuticals Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban’s Bottle of Lies exposes the deceit behind generic-drug manufacturing—and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings? A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world’s greatest public-health innovation has become one of its most astonishing swindles.
From physician and neuroscientist Russell Kennedy, MD comes an award-winning book that offers a revolutionary, life-changing approach to healing anxiety. Break the cycle of anxiety with the newly upgraded and expanded second edition. After years of trying different therapies for his debilitating anxiety without success, Dr. Russell Kennedy had an epiphany: anxiety does not start in the brain. Anxiety starts in the body, where trauma is stored and physical and emotional perception begin. Alarm bells originating in the body are what trigger those anxious thoughts that we call anxiety, and Russ realized that true healing starts only when we learn not to conflate the two. He understood that existing therapies focused only on the mind would never get to the root of the problem—at best, they could help manage symptoms, but they’d never truly heal anxiety. Wanting to make a difference for the millions who suffer from anxiety disorder, Russ created Anxiety Rx, a book that blends his personal story with medical science, neuroscience, and developmental psychology. Readers learn how to sever the connection between the somatic alarm and the flood of anxious thoughts—in the process they begin to heal old trauma and gain a sense of control previously unknown. Russ offers techniques not only for our thinking minds, but for our feeling bodies, changing not just our mindset, but our “body-set.” Unraveling the intricate relationship between anxiety, the body, and the mind, Anxiety Rx offers a profound path toward healing and growth.